Bharat Parenterals Reports Q1FY26 Results, Announces Board Changes and AGM Date
Bharat Parenterals Limited (BPL) reported its Q1 FY26 results. Standalone revenue increased by 2.50% to ₹94.37 crore, while consolidated revenue grew 25.40% to ₹116.00 crore. The company narrowed its consolidated net loss to ₹0.87 crore. BPL projects standalone revenue growth of 12-14% for FY26 with an EBITDA margin of 15-17%. Board changes include Mr. Sanjay Shah's resignation and Mr. Alkesh Jayantilal Shah's appointment as Additional Non-Executive Non-Independent Director. The 32nd AGM is scheduled for September 26, 2025.
12May 25
Bharat Parenterals Q4 FY23: EBITDA Surges Despite Widening Net Loss
Bharat Parenterals Ltd. (BPL) released Q4 FY23 results showing strong operational growth but increased net loss. Revenue rose 47.49% YoY to ₹100.00 crore, EBITDA doubled to ₹22.00 crore with margin improving to 2.14%. However, net loss widened to ₹4.70 crore from ₹0.30 crore in Q4 FY22.